On-Demand Therapy with Proton Pump Inhibitors for Maintenance Treatment of Nonerosive Reflux Disease or Mild Erosive Esophagitis: A Systematic Review and Meta-Analysis

Table 3

Patient characteristics and demographics of included trials.

Study	, on demand/cont	Mean age ± SD	Male (%)
Tsai et al. [19]	(1) Eso 20 mg on demand = 311	51 ± 13.8	46%
	(2) Lanso 15 mg continuous = 311	51 ± 13.8	41.8%
Nagahara et al. [20]	Omeprazole 20 mg continuous = 18	56.2 ± 12.8	21/35 = 60%
	Omeprazole 20 mg on demand = 17
Bayerdörffer et al. [21]	(1) Eso 20 mg on demand = 301	48.2 ± 13.6	40.5%
	(2) Eso 20 mg continuous = 297	47.6 ± 15.1	43.8%
Janssen et al. [22]	Pantoprazole 20 mg on demand = 215	50.4 (SD 13.6)	46.5%
	Pantoprazole 20 mg continuous = 217	51.8 (SD 13.5)	47.5%
Lind et al. [23]	(1) Omeprazole 20 on demand = 139 ()	52 (19–79)	38.1%
	(2) Omeprazole 10 on demand = 142	51 (20–81)	45.8%
	(3) Placebo = 143	48 (20–79)	42.7%
Talley et al. [24]	(1) Eso 20 mg on demand = 170	49 (19–78)	55%
	(2) Placebo on demand = 172	49 (21–79)	57%
Talley et al. [25]	(1) Esomeprazole 40 mg on demand = 293	48	46.1%
	(2) Esomeprazole 20 mg on demand = 282	48.4	47.9%
	(3) Placebo on demand = 146	48.2	39.7%
Bytzer et al. [26]	(1) Rabeprazole 10 mg on demand = 279	47 (0.81 SE)	44%
	(2) Placebo on demand = 139	48 (1.23 SE)	41%
Scholten et al. [27]	Pantoprazole 40 mg on demand = 218	54 ± 14	47.3%
	Pantoprazole 20 mg on demand = 217	52 ± 14	52.5%
	Placebo on demand = 108	52 ± 14	53.7%
Kaspari et al. [28]	Pantoprazole 20 mg on demand = 213	50.7 ± 13.7 years	46%
	Placebo on demand = 226	51.0 ± 14.5 years	43.3%